What’s at Stake for Small Businesses?
As the U.S. government shutdown drags on, small businesses across the country—especially in critical sectors like biotech—are facing dire consequences. Carol Houston, founder of BaysMartin Consulting, a leading biotech consultancy, is among those whose growth plans are on hold as a result of government delays.
Houston’s mission to bridge the gap between innovation and regulation in the life sciences sector is now at a standstill. Her startup, which helps clients navigate the complex world of pharmaceuticals, healthcare, and medical device approvals, is now facing major financial and regulatory hurdles.
The Shutdown’s Ripple Effect: Funding & Regulatory Delays
Houston’s small business was ready to scale up. But with the SBA loan programs frozen and SBIR/STTR grants unavailable, Houston’s growth has been stalled. These essential financial lifelines have been temporarily halted—meaning $170 million in SBA-backed loans is out of reach for 320 small businesses every single day.
Beyond the funding freeze, the Patent and Trademark Office (PTO) is operating, but slower patent approvals are expected due to the shutdown. Houston’s pending AI patent is at risk of further delays, hindering her plans for next-generation biotech development.
Biotech Industry in Crisis: What Does This Mean for Innovation?
As a seasoned biotech contractor advising clients on how to file FDA applications, Houston’s consulting work has dried up as well. With the FDA only conducting mission-critical work, her clients are left without the regulatory guidance they need. Houston points out, “With the uncertainty, the shutdown, and lack of FDA reviews, who needs my help? I need work to sustain my business, or things are going to get tough.”
Houston’s story is a poignant reminder of how fragile the biotech and life sciences sector can be in times of government shutdowns—and how crucial government-backed funding and regulatory oversight are for startups to thrive.
Workforce Delays: New Hires and Product Development on Hold
Houston’s plans to hire a technical team and validate a minimal viable product (MVP) have been delayed indefinitely. She was set to bring on experts to help develop the next stage of her AI-driven biotech solutions—but the shutdown has put everything on pause. “We were just about to submit to the SBA for a loan. I was going to leverage that to secure seed funding and grow. But now, you can’t apply, and all Fed grants are halted,” Houston said, expressing her frustration.
As Houston explains, this isn’t just a setback; it’s a pivotal moment for innovation in biotech, one that could impact future breakthroughs if the current economic gridlock continues.
Shutdown’s Broader Economic Impact: A Wake-Up Call for Small Businesses
When the government partially shut down in 2018, the U.S. economy lost $11 billion, with $3 billion never recovered. Now, with the shutdown entering its second month, small businesses are feeling the economic strain once again.
For small business owners like Houston, the financial uncertainty means missed opportunities, stalled innovation, and lost revenue. The biotech sector, which relies heavily on government-backed funding and FDA approvals, is particularly vulnerable. Houston urges that it’s time for policymakers to recognize the economic harm and take swift action to resolve the deadlock.
The Road Ahead: What’s Next for Small Business Innovation?
Houston is not giving up just yet. She remains hopeful that Congress can reach a resolution that benefits small businesses and ensures that future innovations in sectors like biotech can continue to thrive.
“It’s time for the government shutdown to end. If I can’t generate money, I can’t pay my mortgage. We need a compromise that benefits the American people and small businesses. The roadblocks are stifling our survival,” Houston says.
This situation is a wake-up call for all small business owners and startups to rethink their reliance on government programs and seek out more diverse funding sources.
Key Takeaways for ATBA Members:
- Small businesses in the biotech sector and beyond are facing significant challenges due to the shutdown.
- Funding programs like SBA loans and SBIR/STTR grants have been temporarily halted, leaving businesses without the financial resources needed for growth.
- Innovation in critical sectors like life sciences is being delayed, risking future breakthroughs and market leadership.
- ATBA members must stay informed and proactively explore alternative funding models as we wait for the shutdown to end.
Actionable Insights for Businesses:
As ATBA members navigate these turbulent times, we advise businesses to:
- Diversify funding sources: Explore private-sector investors, venture capital, and international partnerships.
- Engage in cross-border trade: Leverage global business connections to fill the gap left by domestic challenges.
- Prepare for recovery: Start building relationships with key stakeholders now so that once the shutdown ends, your business is poised for rapid growth.
The shutdown’s impact is still unfolding, but one thing is clear: businesses must adapt quickly and innovate to thrive despite the ongoing political gridlock.
